In a 5% w/v oxytetracycline injectable manufacturing line, the API is first equilibrated in a Type 316L stainless steel jacketed vessel at 20–25°C using Water for Injection meeting USP <1231> conductivity and total organic carbon limits. The finished solution corresponds to 50 mg/mL oxytetracycline base equivalent, and the batch formula is built on a per-litre basis rather than a simple percentage because the API lot may be supplied as oxytetracycline dihydrate or oxytetracycline hydrochloride with different assay values. Each 1,000 L medicinal solution requires 50.0 kg of oxytetracycline base activity excluding manufacturing loss, and the actual weighed quantity is corrected using the lot assay and water content. When oxytetracycline dihydrate is used, one equivalent of dilute hydrochloric acid is added slowly under pH control until a clear solution is obtained, because the dihydrate has low aqueous solubility at neutral pH. The exact molar ratio is determined by the batch pH curve, not by a fixed percentage. A representative aqueous vehicle includes 0.1–0.2% w/v sodium metabisulfite as antioxidant and nitrogen blanketing to keep residual oxygen in the headspace below 2% v/v; pH is adjusted with dilute hydrochloric acid or sodium hydroxide to the licensed value, typically in the alkaline range where the ionized form remains in solution but where base-catalyzed epimerization becomes the primary degradation pathway. Sulfite-based antioxidants are omitted where the target species has documented sulfite sensitivity, and in such cases the oxygen control strategy relies solely on nitrogen sparging and headspace flushing. The solution is aseptically filtered through a 0.22 µm PVDF or PES membrane cartridge with pre-use and post-use integrity testing; terminal steam sterilization at 121°C is generally avoided because the degradation rate constant for oxytetracycline in aqueous solution increases sharply with temperature, and the formation of anhydrooxytetracycline and 4-epioxytetracycline would exceed the related-substances limits of the current USP oxytetracycline injection monograph. Filling is performed in an ISO 14644-1 Class 5 zone with Grade A laminar air flow, and the vials are closed under nitrogen. Release testing includes sterility according to USP <71>, bacterial endotoxins according to USP <85>, assay, pH, visible particulates, and related substances. The endotoxin limit is derived from the maximum recommended parenteral dose using the K/M formula, where K is 5 EU/kg for human parenterals; for veterinary products the applicable K may differ and must be justified in the regulatory dossier. The terminal product is filled into Type I amber glass vials at 50 mL or 100 mL nominal volume with a 2–5% overfill to ensure withdrawable volume. The line holds the filtered bulk solution for no more than 8 h at 20–25°C before filling, and temperature excursions above 25°C are recorded as process deviations because they alter the degradation impurity profile.

Does Direct Compression of Oxytetracycline Dihydrate Introduce Dissolution Failures Before the 30-Minute Q-Point?

Direct compression is evaluated only when the oxytetracycline dihydrate lot has a d50 in the 10–50 µm range and a Hausner ratio below 1.35, with moisture content below 3.0% w/w. A representative tablet core for a 250 mg oxytetracycline base equivalent tablet contains 50–70% w/w API, 20–30% w/w microcrystalline cellulose, 2–5% w/w croscarmellose sodium, 0.1–0.5% w/w colloidal silicon dioxide, and 0.5–1.5% w/w magnesium stearate. The API is first passed through a 30-mesh screen with the filler and disintegrant to break soft agglomerates, then blended in a V-blender for 15 min at 15–20 rpm; magnesium stearate is added through a 60-mesh screen and blended for only 3–5 min, because extended lubrication beyond 10 min can coat the API surface with hydrophobic magnesium stearate and slow dissolution. Compression is performed on a rotary tablet press equipped with 10.0 mm round B-tooling, with pre-compression force set to 2–4 kN and main compression force limited to 10–20 kN; target hardness is 50–100 N and friability is maintained below 1.0% according to USP <1216>. Dissolution is tested by USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid; the oxytetracycline tablet monograph acceptance criterion is confirmed against the current compendial text, and typical Q is not less than 80% at 30 min. Aqueous film coating is applied at a product temperature of 38–42°C and an inlet air temperature of 55–65°C; pan speed is 6–12 rpm and spray rate is 5–8 g/min/kg of tablet bed. Coated tablets are packed in opaque PVC/PVDC/aluminium blister cavities. The terminal product is a round biconvex tablet containing 125 mg or 250 mg oxytetracycline base equivalent, with assay and content uniformity tested according to USP <905>.

Because oxytetracycline dihydrate starts to release lattice water above 60°C, hard capsule filling is carried out in a 20–25°C, ≤40% RH processing zone, and the API is not exposed to heated drying after the final blend. Capsule blends are formulated with a finer API fraction, d90 below 150 µm, to reduce segregation on dosator and tamping pin machines. A representative 250 mg capsule fill contains 50–65% w/w oxytetracycline base equivalent, 25–35% w/w lactose monohydrate or mannitol, 2–4% w/w sodium starch glycolate, 0.1–0.3% w/w colloidal silicon dioxide, and 0.5–1.0% w/w magnesium stearate. The final blend is sampled for bulk density, and the fill weight for a size 0 capsule is adjusted to a target range of 350–450 mg depending on tapped density; the empty capsule shell moisture specification is 13.0–16.0% w/w for gelatin or below 8.0% w/w for HPMC shells. Filling is run on an intermittent-motion capsule machine at 60,000–100,000 capsules per hour, with pin depth set to 5–8 mm and final capsule closure locked at a body-to-cap gap of 0.1–0.3 mm. Content uniformity is tested on 10 units at the start, middle, and end of the run according to USP <905>; acceptance value is ≤15.0. Dissolution is tested by USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid. Because oxytetracycline is light-sensitive, filled capsules are transferred to opaque cold-form aluminium blisters with desiccant; the line clearance procedure includes a forced-degradation check for anhydrooxytetracycline when a batch has been held longer than 24 h in bulk containers. The terminal product is a hard capsule containing 250 mg oxytetracycline base equivalent, intended for oral administration with a full glass of water and without dairy products or divalent-cation-containing antacids.

When Wet Granulation Is the Only Route to Uniform Low-Dose Sachet Content

Wet granulation is selected when the API lot has a bulk density below 0.35 g/mL, when direct compression produces capping at hardness above 80 N, or when the intended sachet dose is 125 mg or lower and direct filling cannot meet USP <905> uniformity. The binder is prepared as a 5–10% w/w aqueous dispersion of pregelatinized starch or a 2–5% w/w solution of povidone K-30 in purified water. The dry powder is charged into a high-shear granulator with impeller speed set to 100–200 rpm and chopper speed set to 1500–2500 rpm; binder solution is added at 0.5–1.5 kg/min until the wet mass reaches a moisture content of 12–15% w/w. Wet massing is held for 2–4 min, and the granulated mass is wet-sieved through a 2.0 mm screen before drying. Drying is performed in a fluidized bed dryer with inlet air at 50–60°C and product temperature maintained below 40°C; the final loss on drying is controlled at 1.5–2.5% w/w because residual moisture above 3.0% w/w accelerates the formation of 4-epioxytetracycline during storage at 40°C/75% RH. Dried granules are milled and classified to retain the 12–20 mesh fraction, and fines below 80 mesh are limited to ≤20% w/w to prevent segregation during sachet filling. A representative sachet fill for a 125 mg oxytetracycline base equivalent dose is 1.0–2.0 g of granules, consisting of the API granulation plus sucrose or sorbitol, citric acid, and a fruit flavour. The terminal product is a unit-dose sachet of granules for oral solution, reconstituted to 125 mg/5 mL or 250 mg/5 mL using purified water at 20–25°C. Sachet filling is performed at ≤40% RH on a stick-pack machine with sealing temperature 150–180°C and dwell time 0.3–0.8 s; seal integrity is tested by vacuum leak method according to ASTM F2338. The released granule product is stored in aluminium foil laminate sachets because the moisture vapour transmission rate of the primary package must be below 0.1 g/m²/day to protect the dried granulation.

Oral Suspension Reconstitution Parameters and Preservative Compatibility Limits

Oral suspensions are reconstituted from oxytetracycline granules at 125 mg/5 mL or 250 mg/5 mL by adding purified water in two aliquots with intermittent shaking. The vehicle is buffered to 4.0–6.0 pH; below 4.0 acid-catalyzed dehydration to anhydrooxytetracycline accelerates, and above 6.0 the solubility of the base form decreases and metal-catalyzed oxidation becomes faster. Sodium benzoate is used at 0.1–0.2% w/v with potassium sorbate at 0.1–0.2% w/v; benzoate activity depends on the undissociated acid fraction, so the pH is kept below 4.5 when benzoate is the sole preservative. Calcium carbonate, magnesium trisilicate, aluminium hydroxide, iron salts, and zinc salts are excluded from the formula because tetracyclines form stable chelates with di- and trivalent cations, reducing oral bioavailability and generating visible precipitates. The granule blend contains a dispersant such as xanthan gum or microcrystalline cellulose/sodium carboxymethylcellulose; xanthan gum is dispersed at 0.1–0.3% w/w and hydrated under high shear before the API granulation is added. The reconstituted suspension is stored at 2–8°C, and the in-use shelf-life is confirmed by in-use stability testing; typical in-use limits are 7–10 days when the preservative system is validated. The terminal product is an amber PET bottle with a child-resistant closure and a graduated dosing cup, and the reconstituted suspension is shaken before each dose. Microbiological examination of the preservative effectiveness is performed according to USP <51>; the preservative system must meet the compendial acceptance criteria for oral products. The product is not combined with dairy products, iron supplements, or antacids containing aluminium or magnesium during administration.

At the packaging stage for oxytetracycline solid oral dosage forms, ICH Q1B-compliant primary packaging is selected after confirmatory photostability testing because the molecule degrades under UV and visible light with formation of anhydrooxytetracycline and discolouration. Tablets and capsules are packed in opaque PVC/PVDC/aluminium blisters; granules and sachets are packed in aluminium foil laminate with a moisture vapour transmission rate below 0.1 g/m²/day. HDPE bottles with induction-sealed liners are used for bulk oral powders; bottle wall thickness is 0.8–1.2 mm and the closure contains silica gel desiccant at 1–2 g per 100 mL container volume. The warehouse for finished packs is maintained at ≤25°C and ≤60% RH, and the bulk API is received in double polyethylene bags inside sealed fibre drums with desiccant. If a batch is exposed to fluorescent light for more than 8 h during primary packaging, a photostability sample is pulled and tested for related substances using the current USP oxytetracycline monograph HPLC method. Oxytetracycline tablets, capsules, and granules are not stored in clear glass or clear plastic containers; amber glass or opaque high-density polyethylene is specified. The packaging line is equipped with metal detectors and checkweighers, and the final pack insert states the incompatibility with divalent-cation-containing antacids, iron preparations, and dairy products. The packaging configuration is validated under ICH Q1B conditions at 40°C/75% RH for 6 months and 25°C/60% RH for long-term monitoring; published data for this specific configuration is limited, and the actual shelf-life is assigned only after real-time stability data are generated.